To identify small-molecule drugs that can be used to target XRCC2 against glioma, we explored four small-molecule compounds with potential clinical applications using CMap online tools based on the CGGA RNA-seq dataset: doxazosin, quinostatin, canavanine, and chrysin. Here, XRCC2 is linked to central nervous system cancer.